专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL196848D0 ANTIBODIES DIRECTED TO ??V??6 AND USES THEREOF 未知
公开(公告)号：IL196848D0
公开(公告)日：2011-08-01
申请号：IL19684809
申请日：2009-02-02
申请人： ASTRAZENECA AB , FOLTZ IAN , RINKENBERGER JULIE , ALFRED AVRIL , BARRY SIMON THOMAS , BEDIAN VAHE
IPC分类号： C07K20060101
摘要： Targeted binding agents, such antibodies directed to the antigen αV&bgr;6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αV&bgr;6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.

2. 发明申请

WO03033674A3 HUMAN ANTIBODIES THAT HAVE MN BINDING AND CELL ADHESION-NEUTRALIZING ACTIVITY 审中-公开
标题翻译：具有MN结合和细胞粘附 - 中和活性的人抗体
公开(公告)号：WO03033674A3
公开(公告)日：2003-08-21
申请号：PCT/US0233470
申请日：2002-10-18
申请人： BAYER PHARMACEUTICALS CORP , TAKEUCHI TOSHIHIKO , DUBOIS-STRINGFELLOW NATHALIE , MURPHY JOHN E , RINKENBERGER JULIE
发明人： TAKEUCHI TOSHIHIKO , DUBOIS-STRINGFELLOW NATHALIE , MURPHY JOHN E , RINKENBERGER JULIE
IPC分类号： G01N33/53 , A61K39/395 , A61P35/00 , A61P43/00 , C07K16/00 , C07K16/18 , C07K16/30 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12P21/02
CPC分类号： C07K16/3038 , A61K2039/505 , C07K16/18 , C07K2317/565 , C07K2317/732
摘要： The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods. An example is also provided where a human anti-MN IgG1 mediates tumor cell lysis though antibody-dependent cell-mediated cytotoxicity. Therefore, these antibodies will be useful for the treatment of cancers in which MN is upregulated or can be useful for the diagnosis of cancers in which MN is upregulated.
摘要翻译：本发明由靶向蛋白聚糖结构域内的GEEDLP重复的单克隆人类MN抗体或MN抗体片段组成。 MN细胞表面蛋白的蛋白聚糖结构域含有四个这些相同的GEEDLP重复。通过竞争ELISA验证与所需表位的结合，其中ELISA信号可通过与含有该重复的肽（PGEEDLPGEEDLP）共温育而减毒。这种结合抑制作用也可以使用Biacore测定来验证，其中所需抗体与固定的MN或蛋白聚糖肽的结合可以被肽重复序列抑制。除了与肽重复序列结合之外，人类抗MN抗体还可以抑制CGL-1细胞与MN包被塑料板的细胞粘附。人类抗MN抗体已用于使用FACS和免疫组织化学方法诊断和量化癌细胞和肿瘤中的MN表达。还提供了一个实例，其中人抗MN IgG1通过抗体依赖性细胞介导的细胞毒性介导肿瘤细胞裂解。因此，这些抗体可用于治疗其中MN上调或可用于诊断MN上调的癌症的癌症。

3. 发明申请

WO2008112004A3 ANTIBODIES DIRECTED TO aVß6 AND USES THEREOF 审中-公开
标题翻译：抗体依赖于A6和其使用
公开(公告)号：WO2008112004A3
公开(公告)日：2009-04-02
申请号：PCT/US2007075120
申请日：2007-08-02
申请人： ASTRAZENECA AB , FOLTZ IAN , RINKENBERGER JULIE , ALFRED AVRIL , BARRY SIMON THOMAS , BEDIAN VAHE
发明人： FOLTZ IAN , RINKENBERGER JULIE , ALFRED AVRIL , BARRY SIMON THOMAS , BEDIAN VAHE
IPC分类号： C07K16/28 , C12N5/00 , C12N15/13
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N5/0686 , C12N2501/998
摘要： Targeted binding agents, such antibodies directed to the antigen aVß6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen aVß6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
摘要翻译：描述了靶向结合剂，针对抗原aVβ6的这种抗体以及这些药剂的用途。特别地，公开了针对抗原aVβ6的完全人单克隆抗体。编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 被披露。还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

4. 发明申请

WO2008112004A2 ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF 审中-公开
标题翻译：抗体依赖于A6和其使用
公开(公告)号：WO2008112004A2
公开(公告)日：2008-09-18
申请号：PCT/US2007/075120
申请日：2007-08-02
申请人： ASTRAZENECA AB , FOLTZ, Ian , RINKENBERGER, Julie , ALFRED, Avril , BARRY, Simon Thomas , BEDIAN, Vahe
发明人： FOLTZ, Ian , RINKENBERGER, Julie , ALFRED, Avril , BARRY, Simon Thomas , BEDIAN, Vahe
IPC分类号： C07K16/00
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N5/0686 , C12N2501/998
摘要： Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
摘要翻译：描述了靶向结合剂，针对抗原aVβ6的这种抗体以及这些药剂的用途。特别地，公开了针对抗原aVβ6的完全人单克隆抗体。编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 被披露。还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

5. 发明申请

WO2003033674A2 HUMAN ANTIBODIES THAT HAVE MN BINDING AND CELL ADHESION-NEUTRALIZING ACTIVITY 审中-公开
标题翻译：具有MN结合和细胞粘附中和活性的人抗体
公开(公告)号：WO2003033674A2
公开(公告)日：2003-04-24
申请号：PCT/US2002/033470
申请日：2002-10-18
申请人： BAYER CORPORATION , TAKEUCHI, Toshihiko , DUBOIS-STRINGFELLOW, Nathalie , MURPHY, John, E. , RINKENBERGER, Julie
发明人： TAKEUCHI, Toshihiko , DUBOIS-STRINGFELLOW, Nathalie , MURPHY, John, E. , RINKENBERGER, Julie
IPC分类号： C12N
CPC分类号： C07K16/3038 , A61K2039/505 , C07K16/18 , C07K2317/565 , C07K2317/732
摘要： The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods. An example is also provided where a human anti-MN IgG1 mediates tumor cell lysis though antibody-dependent cell-mediated cytotoxicity. Therefore, these antibodies will be useful for the treatment of cancers in which MN is upregulated or can be useful for the diagnosis of cancers in which MN is upregulated.
摘要翻译：本发明由针对蛋白多糖结构域内的GEEDLP重复的单克隆人MN抗体或MN抗体片段组成。 MN细胞表面蛋白的蛋白多糖结构域包含四个这些相同的GEEDLP重复序列。通过竞争ELISA验证与所需表位的结合，其中ELISA信号可以通过与含有该重复的肽（PGEEDLPGEEDLP）共孵育来减毒。还可以使用Biacore分析验证这种结合抑制，其中所需抗体与固定化的MN或蛋白聚糖肽的结合可被肽重复抑制。除了结合肽重复之外，人抗MN抗体可以抑制CGL-1细胞对MN涂覆的塑料板的细胞粘附。已经使用人抗MN抗体来诊断和定量癌细胞和肿瘤中的MN表达，使用FACS和免疫组织化学方法。还提供了一种实例，其中人抗MN IgG1通过抗体依赖性细胞介导的细胞毒性介导肿瘤细胞裂解。因此，这些抗体可用于治疗其中MN被上调的癌症或可用于诊断MN被上调的癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式